Scandinavian Journal of Pain
Volume 1 , Pages S12-S17 , May 2009

New therapeutic principles for adverse effects on upper and lower gastrointestinal tract in patients treated with opioid analgesics

References 

  1. Allan L , Hays H , Jensen NH , LePolain de Waroux B , Bolt M , Donald R , et al.   Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain . Br Med J . 2001;322:1154–1158
  2. Allan L , et al.   Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain . Spine . 2005;30:2484–2490
  3. Ballantyne JC , LaForge KS . Opioid dependence and addiction during opioid treatment of chronic pain . Pain . 2007;129:235–255
  4. Bell TJ , Panchal SJ , Miaskowski C , Bolge SC , Milanova T , Williamson R . The prevalence, severity, and impact of opioid-induced bowelk dysfunction: Results of a US and European patient survey (PROBE 1) . Pain Med . 2009;10:35–42
  5. Breivik H , Cherny N , Collett B , deConno F , Filbet M , Foubert AJ , et al.   Cancer-related pain: a pan-European survey of prevalence, treatment and patient attitudes . Ann Oncol . 2009 Feb 26; [Epub ahead of print]
  6. Brennscheidt U , Seiler KU , Thomann P . Pharmacokinetics of nortilidine and naloxone after administration of tilidine/naloxone solution or tilitine/naloxone sustained release tablets . Arzneimittelforschung . 2000;50:1015–1022
  7. Brennscheidt U , Brunnmüller U , Proppe D , Thomann P , Seiler KU . Pharmacokinetics of tilidine and naloxone in patients with severe hepatic impairment . Arzneimittelforschung . 2007;57:106–111
  8. Chou R , Fanciullo GJ , Fine PG , Adler JA , Ballantyne JC , Davies P , et al.   Opioid Treatment Guidelines: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain . J Pain . 2009;10:113–130
  9. Colvin L , Forbes K , Fallon M . The difficult pain . Br Med J . 2006;332:1081–1083
  10. Cook SF , Lanza L , Zhou X , Sweeney CT , Goss D , Hollis K , et al.   Gastrointestinal side effects in chronic opioid users: results from a population-based survey . Aliment Pharmacol Ther . 2008;27:1224–1232
  11. Culpepper-Morgan JA , Inturissi CE , Portenoy RK , Foley K , Houde RW , Marsh F , et al.   Treatment of opioid-induced constipation with oral naloxone: a pilot study . Clin Pharmacol Ther . 1992;52:90–95
  12. De Schepper HU , Cremonini F , Park MI , Camilleri M . Opioids and the gut: pharmacology and current clinical experience . Neurogastroenterol Motil . 2004;16:383–394
  13. DeLuca A , Coupar IM . Insights into opioid action in the intestinal tract . Pharmacol Ther . 1996;69:103–112
  14. Delaney CP . Clinical perspective on postoperative ileus and the effect of opiates . Neurogastroenterol Motil (Suppl 2) . 2004;16:61–66
  15. Fahy C , Gan TJ . Postoperative bowel dysfunction . In:  Yuan C-S editors. Handbook of opioid bowel syndrome . London: Haworth Medical Press; 2005;p. 121–153
  16. Holzer P . New approaches to the treatment of opioid-induced constipation . Eur Rev Med Pharmacol Sci . 2008;12(Suppl 1):119–127
  17. Kalso E , Edwards JE , Moore RA , McQuay HJ . Opioids in chronic non-cancer pain: systematic reviewof efficacy and safety . Pain . 2004;112:372–380
  18. Kurz A , Sessler DI . Opioid-induced bowel dysfunction: pathophysiology and potential new therapies . Drugs . 2003;63:649–671
  19. Ling GS , Paul D , Simantov R , Pasternak GW . Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model . Life Sci . 1989;45:1627–1636
  20. Ludwig K , Enker WE , Delaney CP , Wolff BG , Du W , Fort JG , et al.   Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway . Arch Surg . 2008;143:1098–1105
  21. McNicol E , Horowicz-Mehler N , Fisk RA , et al.   Management of opioid side-effects in cancer-related and chronic noncancer pain: a systematic review . J Pain . 2003;4:231–256
  22. McNicol E , Boyce DB , Schumann R , Carr D . Efficacy and safety of mu-opioid anatagonists in the treatment of opioid-induced bowel dysfunction: systematic review and meta-analysis of randomized controlled trials . Pain Med . 2008;9:634–659
  23. Meissner W , Leyendecker P , Mueller-Lissner S , Nadstawek J , Hopp M , Ruckes C , et al.   A randomized controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation . Eur J Pain . 2009;13:56–64
  24. Mythen MG . Postoperative gastrointestinal tract dysfunction . Anesth Analg . 2005;100:196–204
  25. Paulson DM , Kennedy DT , Donovick RA , Carpenter RL , Cherubini M , Techner L , et al.   Alvimopan: an oral, peripherally acting, muopioid receptor antagonist for the treatment of opioid-induced bowel dysfunction a 21-day treatment randomized clinical trial . J Pain . 2005;6:184–192
  26. Portenoy RK , Thomas J , Moehl Boatwright ML , Tran D , Galasso FL , Stambler N , et al.   Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: A double-blind, randomized, parallel group, dose-ranging study . J Pain Symptom Manage . 2008;35:458–468
  27. Quigley C . The role of opioids in cancer pain . Br Med J . 2005;331:825–828
  28. Reimer K , Hopp M , Zenz M , Maier C , Holzer P , Mikus G , et al.   Meeting the challenges of opioid-induced constipation in chronic pain management a novel approach . Pharmacology . 2009;83:10–17
  29. Russell J , Bass P , Goldberg LI , Schuster CR , Merz H . Antagonism of gut, but not central effects of morphine with quarternary narcotic antagonists . Eur J Pharmacol . 1982;78:255–261
  30. Schook JE , Pelton JT , Hruby VJ , Burks TF . Peptide opioid anatagonist separates peripheral and central opioid antitransit effects . J Pharmacol Exp Ther . 1987;243:492–500
  31. Swegle JM , Logemann C . Management of common opioid-induced adverse effects . Am Fam Physician . 2006;74:1347–1354
  32. Taguchi A , Sharma N , Saleem RM , Sessler DI , Carpenter RL , Seyedsadr M , et al.   Selective postoperative inhibition of gastrointestinal opioid receptors . N Engl J Med . 2001;345:935–940
  33. Thomas J , Karver S , Cooney GA , Chamberlain BH , Watt CK , Slatkin NE , et al.   Methylnaltrexone for opioid-induced constipation in advanced illness . N Engl J Med . 2008;358:23321–23343
  34. Thorpe DM . Management of opioid-induced constipation . Curr Pain Headache Rep . 2001;5:237–240
  35. Vodracova D , Leyendecker P , Meissner W , Hopp M , Szombati I , Hermanns K , et al.   Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain . J Pain . 2008;9:1144–1154
  36. Webster L , Jansen JP , Peppin J , Lasko B , Irving G , Morlion B , et al.   Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain . Pain . 2008;137:428–440
  37. Weinstein SH , Pfeffer M , Schor JM , Indindoli L , Mintz M . Metabolites of naloxone in human urine . J Pharm Sci . 1971;60:1567–1568

PII: S1877-8860(09)70004-7

doi: 10.1016/S1877-8860(09)70004-7

Scandinavian Journal of Pain
Volume 1 , Pages S12-S17 , May 2009

Article Tools